Adamas Pharmaceuticals, Inc. (ADMS) in Focus: Stock Rises 7.04% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jul 16, 7:44AM CDT
Adamas Pharmaceuticals, Inc. (ADMS) was a big mover last session, as the company saw its shares rise 7% on the day.
Forest Laboratories Nabs Pediatric Exclusivity for Namenda - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jun 19, 12:20PM CDT
With an additional six months of pediatric exclusivity in the U.S., generic versions of Forest's (FRX) Namenda IR will now enter the market in Jul 2015.
Adamas Pharmaceuticals To Present At JMP Securities Healthcare Conference 2014
PR Newswire - Mon Jun 16, 3:01PM CDT
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that Gregory T. Went, PhD., Chief Executive Officer, will present at the JMP Securities Healthcare Conference 2014 in New York on Tuesday, June 24, 2014 at 1:00 PM Eastern Standard Time.
Will Forest Labs Retain Namenda Market Share? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 13, 11:00AM CDT
Forest Laboratories, Inc. (FRX) has postponed the final phase of switching to late 2014 and intends to continue marketing Namenda IR till the fall of 2014.
Adamas Pharmaceuticals Announces Rater Training Data on ADS-5102 for Parkinson's Disease Patients with Levodopa-Induced Dyskinesia
PR Newswire - Tue Jun 10, 7:31AM CDT
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today presented data on the rater and subject training process utilized in the Phase 2/3 EASED safety and efficacy study of ADS-5102 for the treatment of levodopa-induced dyskinesia (LID), a condition characterized by involuntary movements without purpose that can become severely disabling, rendering individuals with Parkinson's disease unable to perform routine daily tasks.
Adamas secures second US patent for ADS-5102 & related controlled-release amantadine products for LID in patients with Parkinson's disease
M2 - Tue Jun 10, 7:14AM CDT
Pharmaceutical company Adamas Pharmaceuticals (NasdaqGM:ADMS) disclosed on Monday the receipt of the US Patent No. 8,741,343 entitled Method Of Administering Amantadine Prior To A Sleep Period.
Adamas Pharmaceuticals Initiates Phase 3 Trial For ADS-5102 In Parkinson's Disease Patients With Levodopa-Induced Dyskinesia
PR Newswire - Mon Jun 09, 3:01PM CDT
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) announced today that it has initiated a pivotal Phase 3 clinical study of ADS-5102 (amantadine HCl), a high-dose, controlled-release version of amantadine for the treatment of patients with Parkinson's disease who have developed levodopa-induced dyskinesia (LID). LID is a condition characterized by involuntary movements without purpose that can become severely disabling, rendering individuals with Parkinson's disease unable to perform routine daily tasks.
Adamas Pharmaceuticals Announces Data Update At The International Congress Of Parkinson's Disease And Movement Disorders
PR Newswire - Thu May 29, 3:05PM CDT
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced a poster presentation at the 18th International Congress of Parkinson's Disease and Movement Disorders from June 8 to 12, 2014, in Stockholm, Sweden. The poster (abstract #722) is titled "Rater training and data completeness in the study of ADS-5102 in levodopa-induced dyskinesia (EASED study)." The poster presentation will take place during the poster session "Parkinson's Disease: Clinical Trials" on Tuesday, June 10, 2014, from 12:30pm to 2:30pm CET in Stockholm.
Milestone Payments for Adamas - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 22, 4:10PM CDT
Adamas (ADMS) received a milestone payment of $25 million from Forest Labs (FRX) related to MDX-8704.
Adamas Pharmaceuticals awarded USD25m milestone payment for FDA acceptance of MDX-8704 NDA for planned moderate-to-severe dementia of the Alzheimer's type in the US
M2 - Wed May 21, 5:49AM CDT
Pharmaceutical company Adamas Pharmaceuticals (NasdaqGM:ADMS) reported on Tuesday the receipt of a USD25m milestone payment from Forest Laboratories Holdings related to the development of MDX-8704.
Steve Bederman Thought-Technology Leader is Hosting the 2nd in a Webinar Series, "Modernize Your Marketing with the Most Advanced Messaging Solutions in the Marketplace"
PRWeb - Thu Apr 25, 1:07AM CDT
Communication and technology are forever evolving and changing. In the United States alone, approximately 91% of the population has their mobile device within reach 24/7. Additionally, the average user looks at their phone 150 times a day.